PNCA
MCID: PNC035
MIFTS: 82

Pancreatic Cancer (PNCA)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Pancreatic Cancer

MalaCards integrated aliases for Pancreatic Cancer:

Name: Pancreatic Cancer 57 38 12 76 53 75 37 13 13 13 55 43 15
Pancreatic Carcinoma 57 12 53 75 55 44 15 73
Pancreatic Carcinoma, Familial 12 76 73
Familial Pancreatic Carcinoma 53 59 29
Carcinoma of Pancreas 12 29 6
Pancreatic Tumor 12 55 15
Pancreatic Acinar Carcinoma 57 75
Familial Pancreatic Cancer 53 59
Cancer of the Pancreas 53 6
Pancreatic Neoplasm 12 73
Malignant Neoplasm of Body of Pancreas 12
Malignant Neoplasm of Head of Pancreas 12
Malignant Neoplasm of Tail of Pancreas 12
Pancreatic Cancer, Susceptibility to 6
Hereditary Pancreatic Carcinoma 53
Malignant Neoplasm of Pancreas 73
Pancreatic Carcinoma, Somatic 57
Carcinoma of Head of Pancreas 6
Hereditary Pancreatic Cancer 53
Exocrine Pancreas Carcinoma 12
Pancreatic Cancer, Somatic 57
Neoplasm of the Pancreas 29
Pancreatic Neoplasms 44
Ca Body of Pancreas 12
Ca Head of Pancreas 12
Ca Tail of Pancreas 12
Pancreas Carcinoma 53
Cancer, Pancreatic 40
Pancreas Neoplasm 12
Exocrine Cancer 12
Pancreas Cancer 53
Pnca 75

Characteristics:

Orphanet epidemiological data:

59
familial pancreatic carcinoma
Inheritance: Multigenic/multifactorial; Age of onset: Adult;

OMIM:

57
Inheritance:
autosomal dominant
somatic mutation
multifactorial

Miscellaneous:
may be seen with other forms of cancer in a family


HPO:

32
pancreatic cancer:
Inheritance somatic mutation autosomal dominant inheritance


Classifications:



Summaries for Pancreatic Cancer

NIH Rare Diseases : 53 Familial pancreatic cancer (FPC) is the occurrence of pancreatic cancer in two or more first-degree relatives (parent and child, or two siblings). It is sometimes referred to as FPC only when there is not a known hereditary cancer syndrome in an affected family. In familial cases, pancreatic cancer often occurs before age 50 (earlier than other forms of pancreatic cancer). In 60% of cases it occurs within the head of the pancreas. Symptoms of pancreatic cancer are generally non-specific and may include pain in the upper abdomen that radiates to the back; loss of appetite; significant weight loss; and jaundice due to bile duct obstruction. Pancreatic cancer often goes undetected until the advanced stages of the disease, and rapid tumor growth and metastasis are common. A specific genetic cause of FPC (in the absence of a known syndrome) has not been identified. Familial cases of pancreatic cancer due to hereditary conditions may be caused by mutations in any of several genes. Individuals who carry a mutation in one of these genes are often at an increased risk of other types of cancers as well. Currently, only 10-20% of families with FPC will have a mutation identified by genetic testing. Hereditary cancer syndromes and other inherited conditions associated with pancreatic cancer include:BRCA1 hereditary breast and ovarian cancer syndrome BRCA2 hereditary breast and ovarian cancer syndrome Peutz-Jeghers syndrome FAMMM syndrome Lynch syndrome Hereditary pancreatitis In many cases, inheritance of FPC is autosomal dominant; in some cases, is may be multifactorial. It is important to note that pancreatic cancer itself is not inherited, but a genetic predisposition to developing cancer is inherited. Treatment may include surgical resection, chemotherapy, and/or radiotherapy. Resection is the only potential cure, but most patients have advanced, non-resectable tumors by the time of diagnosis.

MalaCards based summary : Pancreatic Cancer, also known as pancreatic carcinoma, is related to pancreas adenocarcinoma and adenocarcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Pancreatic Cancer is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Pancreatic cancer and Gastric cancer. The drugs Afinitor and Gemzar have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and t cells, and related phenotypes are diabetes mellitus and nausea and vomiting

Disease Ontology : 12 An endocrine gland cancer located in the pancreas.

OMIM : 57 Pancreatic cancer shows among the highest mortality rates of any cancer, with a 5-year relative survival rate of less than 5%. By the time of initial diagnosis, metastatic disease is commonly present. Established risk factors include a family history of pancreatic cancer, a medical history of diabetes type 2, and cigarette smoking (summary by Amundadottir et al., 2009). (260350)

MedlinePlus : 43 The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. Pancreatic cancer usually begins in the cells that produce the juices. Some risk factors for developing pancreatic cancer include Smoking Long-term diabetes Chronic pancreatitis Certain hereditary disorders Pancreatic cancer is hard to catch early. It doesn't cause symptoms right away. When you do get symptoms, they are often vague or you may not notice them. They include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. Also, because the pancreas is hidden behind other organs, health care providers cannot see or feel the tumors during routine exams. Doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose it. Because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat. Possible treatments include surgery, radiation, chemotherapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 75 Pancreatic cancer: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

Wikipedia : 76 Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to... more...

Related Diseases for Pancreatic Cancer

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4

Diseases related to Pancreatic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 443)
# Related Disease Score Top Affiliating Genes
1 pancreas adenocarcinoma 33.3 BRCA1 BRCA2 KRAS PALB2 SMAD4 STK11
2 adenocarcinoma 31.4 KRAS MALAT1 SMAD4 STK11 TP53
3 melanoma 31.1 CDKN2B-AS1 MALAT1 MIR15A MIR221 MIR34A MIR34B
4 pancreatic ductal adenocarcinoma 31.0 HOTTIP MALAT1 MIR155 MIR21 MIR221 MIR96
5 gastric cancer 30.9 CDKN2B-AS1 HOTTIP KRAS MALAT1 MIR21 MIR221
6 colorectal cancer 30.8 TP53 STK11 SMAD4 MIR96 MIR34C MIR34B
7 ovarian cancer 30.8 TP53 PALB2 MIR34C MIR34B MIR221 MIR21
8 peutz-jeghers syndrome 30.8 BRCA2 SMAD4 STK11 TP53
9 retinoblastoma 30.7 MALAT1 MIR34A MIR34B TP53
10 cholangiocarcinoma 30.7 KRAS MALAT1 MIR21 SMAD4 TP53
11 breast cancer 30.6 BRCA1 BRCA2 CDKN2B-AS1 HOTTIP KRAS MALAT1
12 lynch syndrome 30.6 BRCA1 BRCA2 KRAS TP53
13 lung cancer 30.5 CDKN2B-AS1 HOTTIP KRAS MALAT1 MIR155 MIR15A
14 pancreas disease 30.5 KRAS SMAD4 TP53
15 small cell cancer of the lung 30.5 HOTTIP MALAT1 MIR21 TP53
16 hepatocellular carcinoma 30.5 CDKN2B-AS1 HOTTIP KRAS MALAT1 MIR155 MIR15A
17 glioma 30.5 BRCA2 CDKN2B-AS1 HOTTIP MALAT1 MIR15A MIR21
18 glioblastoma 30.4 BRCA2 MALAT1 MIR21 MIR221 MIR34A TP53
19 ovarian cancer 1 30.4 BRCA1 BRCA2 KRAS TP53
20 diffuse large b-cell lymphoma 30.3 MIR10A MIR155 MIR21 MIR221 TP53
21 adamantinoma of long bones 30.3 BRCA1 BRCA2 CDKN2B-AS1 HOTTIP KRAS MALAT1
22 prostate cancer 30.3 BRCA1 BRCA2 CDKN2B-AS1 HOTTIP KRAS MALAT1
23 endometrial adenocarcinoma 30.2 KRAS MALAT1 TP53
24 polymyositis 30.2 MIR155 MIR21
25 cervical cancer 30.2 CDKN2B-AS1 MALAT1 MIR21 SMAD4 STK11 TP53
26 bladder cancer 30.2 CDKN2B-AS1 KRAS MALAT1 MIR10A MIR21 MIR221
27 leukemia, acute myeloid 30.2 CDKN2B-AS1 KRAS MALAT1 MIR155 MIR21 MIR221
28 biliary tract neoplasm 30.2 KRAS SMAD4 TP53
29 lung cancer susceptibility 3 30.2 KRAS MALAT1 SMAD4 STK11 TP53
30 acinar cell carcinoma 30.2 BRCA2 SMAD4 TP53
31 gallbladder cancer 30.2 CDKN2B-AS1 KRAS MALAT1 TP53
32 dermatomyositis 30.1 MIR155 MIR21 MIR221
33 myeloma, multiple 30.1 KRAS MALAT1 MIR15A TP53
34 glioblastoma multiforme 30.1 MIR155 MIR21 MIR221 TP53
35 familial adenomatous polyposis 30.0 KRAS SMAD4 TP53
36 pancreatic neuroendocrine tumor 30.0 BRCA2 PALB2
37 melanoma-pancreatic cancer syndrome 12.6
38 pancreatic cancer 4 12.5
39 pancreatic cancer 1 12.4
40 pancreatic cancer 3 12.4
41 pancreatic cancer 2 12.4
42 osteoclast-like giant cell neoplasm of the pancreas 12.3
43 neuroendocrine carcinoma of pancreas 12.3
44 pancreatic cancer, childhood 12.0
45 dysplastic nevus syndrome 11.9
46 pancreatic signet ring cell adenocarcinoma 11.4
47 pancreatitis, hereditary 11.3
48 cystadenocarcinoma 11.3
49 pancreatic intraductal papillary-colloid carcinoma 11.2
50 pancreatic adenosquamous carcinoma 11.1

Comorbidity relations with Pancreatic Cancer via Phenotypic Disease Network (PDN): (show all 12)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Biliary Tract Neoplasm
Cholangitis Cholestasis
Deficiency Anemia Intestinal Obstruction
Pancreatic Agenesis 1 Pancreatitis, Hereditary
Protein-Energy Malnutrition Somatostatinoma

Graphical network of the top 20 diseases related to Pancreatic Cancer:



Diseases related to Pancreatic Cancer

Symptoms & Phenotypes for Pancreatic Cancer

Symptoms via clinical synopsis from OMIM:

57
Abdomen Pancreas:
pancreatic cancer
pancreatic ductal adenocarcinoma

Neoplasia:
pancreatic ductal adenocarcinoma


Clinical features from OMIM:

260350

Human phenotypes related to Pancreatic Cancer:

59 32 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 diabetes mellitus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000819
2 nausea and vomiting 59 32 occasional (7.5%) Occasional (29-5%) HP:0002017
3 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
4 weight loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0001824
5 melanoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0002861
6 jaundice 59 32 frequent (33%) Frequent (79-30%) HP:0000952
7 exocrine pancreatic insufficiency 59 32 hallmark (90%) Very frequent (99-80%) HP:0001738
8 back pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0003418
9 anorexia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002039
10 chronic fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012432
11 colon cancer 59 32 occasional (7.5%) Occasional (29-5%) HP:0003003
12 extrahepatic cholestasis 59 32 frequent (33%) Frequent (79-30%) HP:0012334
13 breast carcinoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0003002
14 pancreatic adenocarcinoma 59 32 obligate (100%) Obligate (100%) HP:0006725
15 lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0002716
16 neoplasm of the liver 59 32 occasional (7.5%) Occasional (29-5%) HP:0002896
17 hepatosplenomegaly 59 32 occasional (7.5%) Occasional (29-5%) HP:0001433
18 functional intestinal obstruction 59 32 frequent (33%) Frequent (79-30%) HP:0005249
19 poor appetite 59 32 hallmark (90%) Very frequent (99-80%) HP:0004396
20 intestinal pseudo-obstruction 59 32 frequent (33%) Frequent (79-30%) HP:0004389
21 intermittent diarrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002254
22 ovarian carcinoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0025318
23 peritoneal abscess 59 32 occasional (7.5%) Occasional (29-5%) HP:0100592
24 elevated hepatic transaminases 59 Occasional (29-5%)
25 neoplasm of the pancreas 32 HP:0002894
26 elevated hepatic transaminase 32 occasional (7.5%) HP:0002910
27 increased level of l-fucose in urine 32 HP:0410067

UMLS symptoms related to Pancreatic Cancer:


nausea and vomiting, constipation, abdominal pain, pruritus, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Pancreatic Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.8 ACVR1B BRCA1 BRCA2 KRAS SMAD4 STK11
2 embryo MP:0005380 9.76 ACVR1B BRCA1 BRCA2 KRAS PALB2 SMAD4
3 integument MP:0010771 9.56 ACVR1B BRCA1 BRCA2 KRAS PALB2 SMAD4
4 neoplasm MP:0002006 9.17 BRCA1 BRCA2 KRAS PALB2 SMAD4 STK11

Drugs & Therapeutics for Pancreatic Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Afinitor 18 49 EVEROLIMUS Novartis March 2009
2
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
3
SecreFlo 18 SECRETIN SECRETIN SYNTHETIC PORCINE Repligen April 2002
4
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006
5
Tarceva 18 49 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004

Drugs for Pancreatic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 697)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53608-75-6
2
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
3
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-03-3
4
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
5
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-23-7 5754
6
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 61825-94-3 43805 6857599 5310940 9887054
7
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
9
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
10
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95058-81-4 60750
11
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33069-62-4 36314
12
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
13
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
14
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
15
Pregabalin Approved, Illicit, Investigational Phase 4,Not Applicable 148553-50-8 5486971
16
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
17
Tramadol Approved, Investigational Phase 4,Not Applicable 27203-92-5 33741
18
Oxycodone Approved, Illicit, Investigational Phase 4,Not Applicable 76-42-6 5284603
19
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51110-01-1, 38916-34-6 53481605
20
Iron Approved Phase 4,Phase 2 7439-89-6 23925
21
Dalteparin Approved Phase 4,Phase 3,Phase 1,Phase 2 9005-49-6
22
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 9005-49-6 772 46507594
23
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
24
Rocuronium Approved Phase 4,Phase 3,Not Applicable 119302-91-9, 143558-00-3 441290
25
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2078-54-8 4943
26
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
27
Meperidine Approved Phase 4 57-42-1 4058
28
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
29
Etomidate Approved Phase 4 33125-97-2 667484 36339
30
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
31
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
32
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
33
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
34
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
35
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2 7440-66-6
36
Desflurane Approved Phase 4,Not Applicable 57041-67-5 42113
37
Isoflurane Approved, Vet_approved Phase 4,Not Applicable 26675-46-7 3763
38
Thrombin Approved, Investigational Phase 4
39
Tegafur Approved, Investigational Phase 4,Phase 2,Phase 1 17902-23-7 5386
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Cyclooxygenase 2 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
45 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
48 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
49 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Omega 3 Fatty Acid Phase 4,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2496)
# Name Status NCT ID Phase Drugs
1 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
2 Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
3 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Unknown status NCT02570529 Phase 4 Albis®;Placebo
4 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
5 Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications Unknown status NCT02775227 Phase 4 Hydrocortisone;Pasireotide
6 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
7 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
8 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
9 Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Completed NCT00920023 Phase 4 Superparamagnetic Iron Oxide Magnetic Resonance Imaging
10 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed NCT00966277 Phase 4 Dalteparin
11 Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy Completed NCT02238847 Phase 4
12 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
13 Prospective Study of Celiac Block Injection: 1 vs. 2 Completed NCT00583479 Phase 4
14 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
15 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
16 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
17 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
18 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
19 RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses Completed NCT02092519 Phase 4
20 Effects of Dexmedetomidine During IRE Procedures for Solid Tumours Completed NCT02044224 Phase 4 Dexmedetomidine
21 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
22 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
23 The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery Completed NCT02728921 Phase 4 5% Albumin infusion 30 min;5% Albumin infusion 3 hours
24 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
25 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
26 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
27 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01525550 Phase 4 sunitinib
28 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed NCT00204373 Phase 4 Lansoprazole (Prevacid)
29 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
30 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Recruiting NCT03257033 Phase 4 Gemcitabine;nab-paclitaxel
31 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
32 CTC Pancreatic Adenocarcinoma Recruiting NCT02335151 Phase 4 Desflurane
33 Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer Recruiting NCT01774019 Phase 4
34 The Effect of Application of TachoSil® in Pancreatoduodenectomy Recruiting NCT03269955 Phase 4 Fibrinogen/thrombin-coated collagen patch
35 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
36 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
37 A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
38 HOPE - A Study to Evaluate the Effect of a Prehabilitation Program on GI Cancer Patients Planning to Undergo Surgery Enrolling by invitation NCT03642093 Phase 4
39 Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer Not yet recruiting NCT02945267 Phase 4 Nimotuzumab plus S1;Placebo plus S1
40 Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study Terminated NCT01768988 Phase 4 Placebo;Pregabalin
41 A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer Terminated NCT00642733 Phase 4 erlotinib [Tarceva];gemcitabine
42 Quality of Life After BDA or Stents to Treat Biliary Obstruction in Pancreas Cancer Terminated NCT01887041 Phase 4
43 Pancreatic Enzyme Suppletion in Pancreatic Cancer Withdrawn NCT01401387 Phase 4
44 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
45 Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer Unknown status NCT02079623 Phase 3
46 Left Celiac Plexus Resection for Pancreatic Cancer at the Body and Tail Unknown status NCT02117895 Phase 3
47 Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Unknown status NCT01836432 Phase 3 FOLFIRINOX;Gemcitabine;Capecitabine;Nab-Paclitaxel
48 A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients Unknown status NCT02854072 Phase 3 GV1001;Gemcitabine;Capecitabine
49 Efficacy and Mechanisms of Acupuncture for Patients With Advanced Pancreatic Cancer Pain Unknown status NCT02510066 Phase 3
50 Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer Unknown status NCT00005871 Phase 3 fluorouracil;rubitecan

Search NIH Clinical Center for Pancreatic Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pancreatic Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Pancreatic Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Pancreatic Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: pancreatic neoplasms

Genetic Tests for Pancreatic Cancer

Genetic tests related to Pancreatic Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Pancreas 29 KRAS SMAD4 STK11 TP53
2 Familial Pancreatic Carcinoma 29
3 Neoplasm of the Pancreas 29

Anatomical Context for Pancreatic Cancer

MalaCards organs/tissues related to Pancreatic Cancer:

41
Pancreas, T Cells, Testes, Lung, Liver, Endothelial, Lymph Node

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Cancer:

19
The Pancreas
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Cancer:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Acini Acinar Cells

Publications for Pancreatic Cancer

Articles related to Pancreatic Cancer:

(show top 50) (show all 7586)
# Title Authors Year
1
Pancreatic Cancer: A Rare Cause of Abdominal Pain in Severe Cystic Fibrosis. ( 30531246 )
2019
2
Emerging Evidence for the Clinical Relevance of Pancreatic Cancer Exosomes. ( 30531240 )
2019
3
Fasting and Glucose-Stimulated Changes in Plasma Glucagon in Pancreatic Cancer: Potential Biomarkers for Detection? ( 30531245 )
2019
4
Spontaneous Regression of Metastatic Pancreatic Cancer: A Role for Recurrent Inflammation. ( 30531247 )
2019
5
Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rationale and Methodology for the DETECT Study From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer: Erratum. ( 30531249 )
2019
6
Characterization of zolbetuximab in pancreatic cancer models. ( 30546962 )
2019
7
Dysregulation of key microRNAs in pancreatic cancer development. ( 30551350 )
2019
8
Subcutaneous Inoculation of 3D Pancreatic Cancer Spheroids Results in Development of Reproducible Stroma-Rich Tumors. ( 30554606 )
2019
9
Induction chemotherapy in borderline (non-)resectable pancreatic cancer: a unique window of opportunity for understanding pancreatic cancer. ( 30465927 )
2019
10
TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). ( 30471651 )
2019
11
HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway. ( 30366522 )
2019
12
An In Vitro Three-Dimensional Organotypic Model to Analyze Peripancreatic Fat Invasion in Pancreatic Cancer: A Culture System Based on Collagen Gel Embedding. ( 30378049 )
2019
13
Evaluating Stress Granules in Pancreatic Cancer In Vitro and In Vivo. ( 30378055 )
2019
14
Methods for Monitoring Macroautophagy in Pancreatic Cancer Cells. ( 30378056 )
2019
15
Measurement of Reactive Oxygen Species by Fluorescent Probes in Pancreatic Cancer Cells. ( 30378057 )
2019
16
Evaluating the Metabolic Alterations in Pancreatic Cancer. ( 30378058 )
2019
17
Evaluation of Post-transcriptional Gene Regulation in Pancreatic Cancer Cells: Studying RNA Binding Proteins and Their mRNA Targets. ( 30378060 )
2019
18
Pancreatic Acinar-to-Ductal Metaplasia and Pancreatic Cancer. ( 30378064 )
2019
19
Molecular and Physiological Evaluation of Pancreatic Cancer-Induced Cachexia. ( 30378066 )
2019
20
Dexamethasone-induced inhibition of miR-132 via methylation promotes TGF-β-driven progression of pancreatic cancer. ( 30387838 )
2019
21
Danthron suppresses autophagy and sensitizes pancreatic cancer cells to doxorubicin. ( 30389604 )
2019
22
Endoscopic Management of Pancreatic Cancer. ( 30414679 )
2019
23
A novel binuclear hydrazone-based Cd(II) complex is a strong pro-apoptotic inducer with significant activity against 2D and 3D pancreatic cancer stem cells. ( 30352315 )
2019
24
Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. ( 30365057 )
2019
25
Identification of a 5‑microRNA signature and hub miRNA‑mRNA interactions associated with pancreatic cancer. ( 30365134 )
2019
26
Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer. ( 30365143 )
2019
27
Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate-copper complex loaded into hyaluronic acid decorated liposomes. ( 30267751 )
2019
28
Machine learning improves classification of preclinical models of pancreatic cancer with chemical exchange saturation transfer MRI. ( 30277270 )
2019
29
Characterization and proteomic profiling of pancreatic cancer-derived serum exosomes. ( 30160795 )
2019
30
Using photography to explore psychological distress in patients with pancreatic cancer and their caregivers: a qualitative study. ( 29959574 )
2019
31
The FGF1/CPP-C chimera protein protects against intestinal adverse effects of C-ion radiotherapy without exacerbating pancreatic carcinoma. ( 30406211 )
2019
32
EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway. ( 30551529 )
2019
33
Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells. ( 29978609 )
2018
34
IL-35 hinders endogenous anti-tumor T cell immunity and responsiveness to immunotherapy in pancreatic cancer. ( 29980536 )
2018
35
MiR-29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125. ( 29978477 )
2018
36
Selective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barcodes and a bioinformatic variant filter. ( 29451897 )
2018
37
Hepatobiliary and Pancreatic: Pancreatic cancer with elevated serum IgG4 level due to multiple myeloma mimicking localized autoimmune pancreatitis. ( 29761833 )
2018
38
3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer. ( 29805624 )
2018
39
Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer. ( 29442211 )
2018
40
A case of gastric wall implantation caused by EUS-FNA 22 months after pancreatic cancer resection. ( 29451172 )
2018
41
Pathologic Evaluation of Surgical Margins in Pancreatic Cancer Specimens Using Color Coding With Tissue Marking Dyes. ( 29975353 )
2018
42
Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3I^/Snail signaling. ( 29980787 )
2018
43
What Patients Look for When Browsing Online for Pancreatic Cancer: The Bait Behind the Byte. ( 29971463 )
2018
44
LIF Drives Neural Remodeling in Pancreatic Cancer and Offers a New Candidate Biomarker. ( 29269518 )
2018
45
Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. ( 27742762 )
2018
46
Acute Pancreatitis and Pancreatic Cancer Risk: A Nationwide Matched-cohort Study in Denmark. ( 29432727 )
2018
47
Pancreatic stellate cells reorganize matrix components and lead pancreatic cancer invasion via the function of Endo180. ( 29061505 )
2018
48
Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey. ( 29235054 )
2018
49
Focal Autoimmune Pancreatitis Mimicking Pancreatic Cancer on FDG PET/CT Imaging. ( 29189377 )
2018
50
Treatment of pancreatic cancer with intravenous vitamin C: a case report. ( 29438178 )
2018

Variations for Pancreatic Cancer

ClinVar genetic disease variations for Pancreatic Cancer:

6 (show top 50) (show all 244)
# Gene Variation Type Significance SNP ID Assembly Location
1 RBBP8 NM_002894.2(RBBP8): c.1009A> G (p.Lys337Glu) single nucleotide variant Uncertain significance rs121434388 GRCh37 Chromosome 18, 20572799: 20572799
2 RBBP8 NM_002894.2(RBBP8): c.1009A> G (p.Lys337Glu) single nucleotide variant Uncertain significance rs121434388 GRCh38 Chromosome 18, 22992836: 22992836
3 STK11 NM_000455.4(STK11): c.108C> A (p.Tyr36Ter) single nucleotide variant Pathogenic rs137853079 GRCh37 Chromosome 19, 1207020: 1207020
4 STK11 NM_000455.4(STK11): c.108C> A (p.Tyr36Ter) single nucleotide variant Pathogenic rs137853079 GRCh38 Chromosome 19, 1207021: 1207021
5 STK11 NM_000455.4(STK11): c.650delC (p.Pro217Argfs) deletion Pathogenic rs397518442 GRCh37 Chromosome 19, 1220632: 1220632
6 STK11 NM_000455.4(STK11): c.650delC (p.Pro217Argfs) deletion Pathogenic rs397518442 GRCh38 Chromosome 19, 1220633: 1220633
7 STK11 NM_000455.4(STK11): c.936delA (p.Lys312Asnfs) deletion Pathogenic rs397518443 GRCh37 Chromosome 19, 1222999: 1222999
8 STK11 NM_000455.4(STK11): c.936delA (p.Lys312Asnfs) deletion Pathogenic rs397518443 GRCh38 Chromosome 19, 1223000: 1223000
9 ACVR1B NM_020328.3(ACVR1B): c.1282_1286delGATGA (p.Asp428Asnfs) deletion Pathogenic rs387906389 GRCh37 Chromosome 12, 52380624: 52380628
10 ACVR1B NM_020328.3(ACVR1B): c.1282_1286delGATGA (p.Asp428Asnfs) deletion Pathogenic rs387906389 GRCh38 Chromosome 12, 51986840: 51986844
11 ACVR1B NM_020328.3(ACVR1B): c.1385-502_1515+24del deletion Pathogenic GRCh37 Chromosome 12, 52385145: 52385801
12 ACVR1B NM_020328.3(ACVR1B): c.1385-502_1515+24del deletion Pathogenic GRCh38 Chromosome 12, 51991361: 51992017
13 SMAD4 NM_005359.5(SMAD4): c.1072G> T (p.Gly358Ter) single nucleotide variant Pathogenic rs121912576 GRCh37 Chromosome 18, 48591909: 48591909
14 SMAD4 NM_005359.5(SMAD4): c.1072G> T (p.Gly358Ter) single nucleotide variant Pathogenic rs121912576 GRCh38 Chromosome 18, 51065539: 51065539
15 SMAD4 NM_005359.5(SMAD4): c.1477G> C (p.Asp493His) single nucleotide variant Pathogenic rs121912578 GRCh37 Chromosome 18, 48604655: 48604655
16 SMAD4 NM_005359.5(SMAD4): c.1477G> C (p.Asp493His) single nucleotide variant Pathogenic rs121912578 GRCh38 Chromosome 18, 51078285: 51078285
17 SMAD4 NM_005359.5(SMAD4): c.1543A> T (p.Arg515Ter) single nucleotide variant Pathogenic rs121912579 GRCh37 Chromosome 18, 48604721: 48604721
18 SMAD4 NM_005359.5(SMAD4): c.1543A> T (p.Arg515Ter) single nucleotide variant Pathogenic rs121912579 GRCh38 Chromosome 18, 51078351: 51078351
19 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
20 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
21 TP53 NM_000546.5(TP53): c.105G> T (p.Leu35Phe) single nucleotide variant Pathogenic rs121912661 GRCh37 Chromosome 17, 7579582: 7579582
22 TP53 NM_000546.5(TP53): c.105G> T (p.Leu35Phe) single nucleotide variant Pathogenic rs121912661 GRCh38 Chromosome 17, 7676264: 7676264
23 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
24 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
25 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
26 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 GRCh38 Chromosome 12, 25245350: 25245350
27 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 GRCh37 Chromosome 17, 41209082: 41209082
28 BRCA1 NM_007294.3(BRCA1): c.5266dupC (p.Gln1756Profs) duplication Pathogenic rs80357906 GRCh38 Chromosome 17, 43057065: 43057065
29 SMAD4 NM_005359.5(SMAD4): c.1236C> G (p.Tyr412Ter) single nucleotide variant Pathogenic rs121912577 GRCh37 Chromosome 18, 48593485: 48593485
30 SMAD4 NM_005359.5(SMAD4): c.1236C> G (p.Tyr412Ter) single nucleotide variant Pathogenic rs121912577 GRCh38 Chromosome 18, 51067115: 51067115
31 BRCA1 NM_007294.3(BRCA1): c.4456A> T (p.Ser1486Cys) single nucleotide variant Uncertain significance rs397507232 GRCh37 Chromosome 17, 41228533: 41228533
32 BRCA1 NM_007294.3(BRCA1): c.4456A> T (p.Ser1486Cys) single nucleotide variant Uncertain significance rs397507232 GRCh38 Chromosome 17, 43076516: 43076516
33 BRCA2 NM_000059.3(BRCA2): c.353G> A (p.Arg118His) single nucleotide variant Conflicting interpretations of pathogenicity rs80358603 GRCh37 Chromosome 13, 32899249: 32899249
34 BRCA2 NM_000059.3(BRCA2): c.353G> A (p.Arg118His) single nucleotide variant Conflicting interpretations of pathogenicity rs80358603 GRCh38 Chromosome 13, 32325112: 32325112
35 BRCA2 NM_000059.3(BRCA2): c.6405_6409delCTTAA (p.Asn2135Lysfs) deletion Pathogenic rs80359584 GRCh37 Chromosome 13, 32914897: 32914901
36 BRCA2 NM_000059.3(BRCA2): c.6405_6409delCTTAA (p.Asn2135Lysfs) deletion Pathogenic rs80359584 GRCh38 Chromosome 13, 32340760: 32340764
37 BRCA2 NM_000059.3(BRCA2): c.6325G> A (p.Val2109Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs79456940 GRCh37 Chromosome 13, 32914817: 32914817
38 BRCA2 NM_000059.3(BRCA2): c.6325G> A (p.Val2109Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs79456940 GRCh38 Chromosome 13, 32340680: 32340680
39 BRCA2 NM_000059.3(BRCA2): c.10150C> T (p.Arg3384Ter) single nucleotide variant Conflicting interpretations of pathogenicity rs397507568 GRCh37 Chromosome 13, 32972800: 32972800
40 BRCA2 NM_000059.3(BRCA2): c.10150C> T (p.Arg3384Ter) single nucleotide variant Conflicting interpretations of pathogenicity rs397507568 GRCh38 Chromosome 13, 32398663: 32398663
41 BRCA2 NM_000059.3(BRCA2): c.440A> G (p.Gln147Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs80358674 GRCh37 Chromosome 13, 32900252: 32900252
42 BRCA2 NM_000059.3(BRCA2): c.440A> G (p.Gln147Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs80358674 GRCh38 Chromosome 13, 32326115: 32326115
43 BRCA2 NM_000059.3(BRCA2): c.4525C> T (p.Gln1509Ter) single nucleotide variant Pathogenic rs80358683 GRCh37 Chromosome 13, 32913017: 32913017
44 BRCA2 NM_000059.3(BRCA2): c.4525C> T (p.Gln1509Ter) single nucleotide variant Pathogenic rs80358683 GRCh38 Chromosome 13, 32338880: 32338880
45 BRCA2 NM_000059.3(BRCA2): c.6408_6414delAAATGTT (p.Asn2137Lysfs) deletion Pathogenic rs397507851 GRCh37 Chromosome 13, 32914900: 32914906
46 BRCA2 NM_000059.3(BRCA2): c.6408_6414delAAATGTT (p.Asn2137Lysfs) deletion Pathogenic rs397507851 GRCh38 Chromosome 13, 32340763: 32340769
47 BRCA2 NM_000059.3(BRCA2): c.7522G> A (p.Gly2508Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs80358978 GRCh37 Chromosome 13, 32930651: 32930651
48 BRCA2 NM_000059.3(BRCA2): c.7522G> A (p.Gly2508Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs80358978 GRCh38 Chromosome 13, 32356514: 32356514
49 BRCA1 NM_007294.3(BRCA1): c.811G> A (p.Val271Met) single nucleotide variant Conflicting interpretations of pathogenicity rs80357244 GRCh37 Chromosome 17, 41246737: 41246737
50 BRCA1 NM_007294.3(BRCA1): c.811G> A (p.Val271Met) single nucleotide variant Conflicting interpretations of pathogenicity rs80357244 GRCh38 Chromosome 17, 43094720: 43094720

Cosmic variations for Pancreatic Cancer:

9 (show top 50) (show all 80)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6920561 TRAF7 pancreas,NS,carcinoma,acinar carcinoma c.1187A>G p.Q396R 16:2173972-2173972 32
2 COSM6955726 TRAF2 pancreas,NS,carcinoma,acinar carcinoma c.876G>T p.E292D 9:136920431-136920431 32
3 COSM6977589 SPOP pancreas,NS,carcinoma,acinar carcinoma c.838-1G>A p.? 17:49602008-49602008 32
4 COSM6977592 SMARCA4 pancreas,NS,carcinoma,acinar carcinoma c.1369G>A p.E457K 19:10991273-10991273 32
5 COSM4754647 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1600C>T p.Q534* 18:51078408-51078408 32
6 COSM6784678 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1597C>A p.L533I 18:51078405-51078405 32
7 COSM14249 SMAD4 pancreas,NS,carcinoma,acinar carcinoma c.1156G>C p.G386R 18:51067035-51067035 32
8 COSM6955723 SETD2 pancreas,NS,carcinoma,acinar carcinoma c.2816C>A p.S939* 3:47120311-47120311 32
9 COSM6977590 RPTOR pancreas,NS,carcinoma,acinar carcinoma c.485G>A p.G162E 17:80707977-80707977 32
10 COSM6977587 ROS1 pancreas,NS,carcinoma,acinar carcinoma c.5756C>A p.A1919D 6:117321280-117321280 32
11 COSM6934092 RARA pancreas,NS,carcinoma,acinar carcinoma c.995T>A p.I332N 17:40354489-40354489 32
12 COSM6974631 RARA pancreas,NS,carcinoma,acinar carcinoma c.1285G>T p.G429C 17:40356122-40356122 32
13 COSM6941250 PTPRD pancreas,NS,carcinoma,acinar carcinoma c.5594G>C p.R1865T 9:8319907-8319907 32
14 COSM5327 PTEN pancreas,NS,carcinoma,acinar carcinoma c.740T>A p.L247* 10:87957958-87957958 32
15 COSM6955728 PTEN pancreas,NS,carcinoma,acinar carcinoma c.686C>A p.S229* 10:87957904-87957904 32
16 COSM6927948 PLCG2 pancreas,NS,carcinoma,acinar carcinoma c.3622G>A p.E1208K 16:81956746-81956746 32
17 COSM6955738 PLCG2 pancreas,NS,carcinoma,acinar carcinoma c.2462C>A p.S821Y 16:81927126-81927126 32
18 COSM763 PIK3CA pancreas,NS,carcinoma,acinar carcinoma c.1633G>A p.E545K 3:179218303-179218303 32
19 COSM4186192 PBRM1 pancreas,NS,carcinoma,acinar carcinoma c.2884G>T p.D962Y 3:52589151-52589151 32
20 COSM6955743 PAK5 pancreas,NS,carcinoma,acinar carcinoma c.1657C>A p.L553M 20:9557694-9557694 32
21 COSM6961498 NKX2-1 pancreas,NS,carcinoma,acinar carcinoma c.578A>T p.H193L 14:36517816-36517816 32
22 COSM6976390 NFE2L2 pancreas,NS,carcinoma,acinar carcinoma c.838G>T p.D280Y 2:177231765-177231765 32
23 COSM6977500 NF1 pancreas,NS,carcinoma,acinar carcinoma c.7786G>T p.V2596F 17:31357007-31357007 32
24 COSM532 KRAS pancreas,NS,carcinoma,acinar carcinoma c.38G>A p.G13D 12:25245347-25245347 32
25 COSM520 KRAS pancreas,NS,carcinoma,acinar carcinoma c.35G>T p.G12V 12:25245350-25245350 32
26 COSM521 KRAS pancreas,NS,carcinoma,acinar carcinoma c.35G>A p.G12D 12:25245350-25245350 32
27 COSM221052 KMT2D pancreas,NS,carcinoma,acinar carcinoma c.9187C>T p.Q3063* 12:49037359-49037359 32
28 COSM6936263 KMT2D pancreas,NS,carcinoma,acinar carcinoma c.10090C>T p.Q3364* 12:49033805-49033805 32
29 COSM6921306 INPP4B pancreas,NS,carcinoma,acinar carcinoma c.292T>G p.F98V 4:142403018-142403018 32
30 COSM6955721 IKBKE pancreas,NS,carcinoma,acinar carcinoma c.1956G>T p.Q652H 1:206493289-206493289 32
31 COSM28747 IDH1 pancreas,NS,carcinoma,acinar carcinoma c.394C>T p.R132C 2:208248389-208248389 32
32 COSM3430388 HIST1H3B pancreas,NS,carcinoma,acinar carcinoma c.258G>C p.Q86H 6:26031803-26031803 32
33 COSM6934091 GRIN2A pancreas,NS,carcinoma,acinar carcinoma c.527T>A p.I176N 16:9938439-9938439 32
34 COSM27895 GNAS pancreas,NS,carcinoma,acinar carcinoma c.602G>A p.R201H 20:58909366-58909366 32
35 COSM6955729 FGF19 pancreas,NS,carcinoma,acinar carcinoma c.574C>A p.L192M 11:69699339-69699339 32
36 COSM4967292 FAT1 pancreas,NS,carcinoma,acinar carcinoma c.11216C>T p.A3739V 4:186603310-186603310 32
37 COSM6934088 EGFR pancreas,NS,carcinoma,acinar carcinoma c.3541G>C p.A1181P 7:55205525-55205525 32
38 COSM6960278 EED pancreas,NS,carcinoma,acinar carcinoma c.445A>T p.T149S 11:86256405-86256405 32
39 COSM5689 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.134C>G p.S45C 3:41224646-41224646 32
40 COSM5676 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.122C>T p.T41I 3:41224634-41224634 32
41 COSM5667 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.134C>T p.S45F 3:41224646-41224646 32
42 COSM5679 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.110C>G p.S37C 3:41224622-41224622 32
43 COSM5686 CTNNB1 pancreas,NS,carcinoma,acinar carcinoma c.100G>A p.G34R 3:41224612-41224612 32
44 COSM6955735 CD276 pancreas,NS,carcinoma,acinar carcinoma c.308G>T p.G103V 15:73702483-73702483 32
45 COSM6955741 AXIN2 pancreas,NS,carcinoma,acinar carcinoma c.1665C>A p.C555* 17:65537371-65537371 32
46 COSM6955736 AXIN1 pancreas,NS,carcinoma,acinar carcinoma c.1210G>T p.E404* 16:304348-304348 32
47 COSM6977595 ATRX pancreas,NS,carcinoma,acinar carcinoma c.5438G>A p.G1813E 23:77618816-77618816 32
48 COSM6955731 ATM pancreas,NS,carcinoma,acinar carcinoma c.6415G>T p.E2139* 11:108320021-108320021 32
49 COSM19021 APC pancreas,NS,carcinoma,acinar carcinoma c.4330C>T p.Q1444* 5:112839924-112839924 32
50 COSM94388 pancreas,NS,carcinoma,acinar carcinoma c.2531G>A p.R844H 20:58909366-58909366 32

Copy number variations for Pancreatic Cancer from CNVD:

7 (show top 50) (show all 15981)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13839 1 100027661 100101597 Gain and loss AGL Pancreatic cancer
2 13849 1 100147561 100201027 Gain and loss SLC35A3 Pancreatic cancer
3 13857 1 100215810 100260948 Gain and loss HIAT1 Pancreatic cancer
4 13861 1 100261125 100310532 Gain and loss SASS6 Pancreatic cancer
5 13862 1 10027309 10175557 Gain and loss UBE4B Pancreatic cancer
6 13871 1 100326522 100355822 Gain and loss LRRC39 Pancreatic cancer
7 13875 1 100372897 100427397 Gain and loss DBT Pancreatic cancer
8 13880 1 100443784 100469348 Gain and loss RTCD1 Pancreatic cancer
9 13887 1 100530068 100697853 Gain and loss CDC14A Pancreatic cancer
10 13901 1 100715714 100719589 Gain and loss GPR88 Pancreatic cancer
11 13916 1 100897318 100916618 Gain and loss VCAM1 Pancreatic cancer
12 13924 1 101049969 101073575 Gain and loss EXTL2 Pancreatic cancer
13 13925 1 101073653 101157013 Gain and loss SLC30A7 Pancreatic cancer
14 13931 1 101167641 101203392 Gain and loss DPH5 Pancreatic cancer
15 13942 1 101414596 101419094 Gain and loss EDG1 Pancreatic cancer
16 13966 1 101980154 102174569 Gain and loss OLFM3 Pancreatic cancer
17 13979 1 10205097 10375920 Gain and loss KIF1B Pancreatic cancer
18 14027 1 103055016 103286073 Gain and loss COL11A1 Pancreatic cancer
19 14059 1 103780424 103834168 Gain and loss RNPC3 Pancreatic cancer
20 14081 1 103871529 103880389 Gain and loss AMY2A Pancreatic cancer
21 14091 1 103910910 103919188 Gain and loss AMY1A Pancreatic cancer
22 14093 1 10393351 10414467 Gain and loss PGD Pancreatic cancer
23 14151 1 10424425 10446476 Gain and loss APITD1 Pancreatic cancer
24 14168 1 10454871 10466879 Gain and loss DFFA Pancreatic cancer
25 14176 1 10469278 10625079 Gain and loss PEX14 Pancreatic cancer
26 14277 1 10641535 10790973 Gain and loss CASZ1 Pancreatic cancer
27 14348 1 107311380 107313956 Gain and loss HRMT1L6 Pancreatic cancer
28 14354 1 107395591 107665249 Gain and loss NTNG1 Pancreatic cancer
29 14396 1 107825832 108219580 Gain and loss VAV3 Pancreatic cancer
30 14412 1 107915304 108309068 Gain or loss VAV3 Pancreas cancer
31 14435 1 108389491 108454940 Gain and loss SLC25A24 Pancreatic cancer
32 14445 1 108477129 108498715 Gain and loss NBPF4 Pancreatic cancer
33 14472 1 108630504 108640564 Gain and loss NBPF5 Pancreatic cancer
34 14486 1 108815093 108889808 Gain and loss FAM102B Pancreatic cancer
35 14495 1 108947005 108956462 Gain and loss PRPF38B Pancreatic cancer
36 14496 1 108977028 108997407 Gain and loss FNDC7 Pancreatic cancer
37 14498 1 109001350 109064190 Gain and loss STXBP3 Pancreatic cancer
38 14509 1 109131869 109185060 Gain and loss GPSM2 Pancreatic cancer
39 14514 1 109184172 109218121 Gain and loss CLCC1 Pancreatic cancer
40 14518 1 109224882 109296777 Gain and loss WDR47 Pancreatic cancer
41 14530 1 109319187 109330611 Gain and loss TAF13 Pancreatic cancer
42 14538 1 109368575 109461639 Gain and loss KIAA1324 Pancreatic cancer
43 14554 1 109468582 109492827 Gain and loss SARS Pancreatic cancer
44 14558 1 109504683 109530414 Gain and loss CELSR2 Pancreatic cancer
45 14588 1 109568465 109652615 Gain and loss SORT1 Pancreatic cancer
46 14603 1 109594163 109619901 Gain or loss CELSR2 Pancreas cancer
47 14615 1 109656520 109681079 Gain and loss PSMA5 Pancreatic cancer
48 14617 1 109721142 109734212 Gain and loss SYPL2 Pancreatic cancer
49 14619 1 109738603 109747396 Gain and loss ATXN7L2 Pancreatic cancer
50 14623 1 109748763 109755097 Gain and loss CYB561D1 Pancreatic cancer

Expression for Pancreatic Cancer

Search GEO for disease gene expression data for Pancreatic Cancer.

Pathways for Pancreatic Cancer

Pathways related to Pancreatic Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Pancreatic cancer hsa05212

GO Terms for Pancreatic Cancer

Cellular components related to Pancreatic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.23 MIR10A MIR155 MIR15A MIR21 MIR221 MIR34A
2 lateral element GO:0000800 8.96 BRCA1 BRCA2

Biological processes related to Pancreatic Cancer according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.95 MIR15A MIR21 MIR221 SMAD4 STK11 TP53
2 negative regulation of gene expression GO:0010629 9.94 ACVR1B CDKN2B-AS1 MIR155 MIR21
3 positive regulation of gene expression GO:0010628 9.87 ACVR1B BRCA1 CDKN2B-AS1 KRAS MIR21 MIR34A
4 DNA recombination GO:0006310 9.83 BRCA1 BRCA2 PALB2
5 negative regulation of cell growth GO:0030308 9.83 ACVR1B SMAD4 STK11 TP53
6 transforming growth factor beta receptor signaling pathway GO:0007179 9.82 ACVR1B MIR21 SMAD4
7 double-strand break repair via homologous recombination GO:0000724 9.81 BRCA1 BRCA2 PALB2
8 negative regulation of angiogenesis GO:0016525 9.81 MIR10A MIR15A MIR21 MIR34A
9 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.79 MIR21 MIR221 SMAD4
10 negative regulation of protein kinase B signaling GO:0051898 9.78 MIR34A MIR34B MIR34C
11 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.76 MIR155 MIR15A MIR221
12 positive regulation of epithelial to mesenchymal transition GO:0010718 9.75 MIR21 MIR221 SMAD4
13 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.72 MIR15A MIR34A MIR96
14 positive regulation of cell cycle arrest GO:0071158 9.67 BRCA1 MIR34A TP53
15 positive regulation of histone H3-K4 methylation GO:0051571 9.65 BRCA1 SMAD4
16 inner cell mass cell proliferation GO:0001833 9.64 BRCA2 PALB2
17 regulation of protein kinase B signaling GO:0051896 9.63 MIR21 STK11
18 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.63 MIR15A MIR21 MIR34A
19 positive regulation of histone H3-K9 acetylation GO:2000617 9.61 BRCA1 SMAD4
20 positive regulation of cellular senescence GO:2000774 9.61 KRAS MIR10A MIR34A
21 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.6 MIR155 MIR221
22 negative regulation of regulatory T cell differentiation GO:0045590 9.59 MIR155 MIR21
23 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.58 BRCA1 BRCA2 TP53
24 chordate embryonic development GO:0043009 9.57 BRCA1 BRCA2
25 negative regulation of cell adhesion molecule production GO:0060354 9.56 MIR155 MIR221
26 negative regulation of sprouting angiogenesis GO:1903671 9.56 MIR221 MIR34A MIR34B MIR34C
27 miRNA mediated inhibition of translation GO:0035278 9.55 MIR155 MIR15A MIR21 MIR221 MIR96
28 negative regulation of vascular wound healing GO:0061044 9.54 MIR155 MIR34A
29 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.54 MIR155 MIR34B MIR34C
30 gene silencing by miRNA GO:0035195 9.28 MIR10A MIR155 MIR15A MIR21 MIR221 MIR34A
31 positive regulation of connective tissue replacement GO:1905205 9.26 MIR155 MIR34A MIR34B MIR34C
32 cellular response to DNA damage stimulus GO:0006974 10.02 BRCA1 BRCA2 PALB2 STK11 TP53

Molecular functions related to Pancreatic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR10A MIR155 MIR15A MIR21 MIR221 MIR34A
2 LRR domain binding GO:0030275 8.96